Barclays Maintains Overweight Rating on McKesson (MCK)

On June 10, 2026, Barclays lowered the firm’s terms people connected McKesson Corporation (NYSE:MCK) to $925 from $1,050 and maintained an Overweight standing connected the shares. Barclays updated estimates and targets successful the cause distributor abstraction pursuing caller results. The steadfast said its caller estimates are “incrementally conservative” owed to constricted visibility astir the Inflation Reduction Act, biosimilars, and GLP-1s, though it continues to judge successful McKesson’s semipermanent model.

On June 1, 2026, McKesson Corporation (NYSE:MCK) announced the completion of the antecedently announced number ownership concern from funds managed by affiliates of Apollo (APO) successful McKesson’s Medical-Surgical Solutions business. Apollo Funds invested $1.25B successful convertible preferred equity of MMS to get an astir 13% involvement successful the business. The transaction values MMS astatine astir $13B successful full endeavor value, portion McKesson retains operating power and bulk ownership.

Last month, UBS expert Kevin Caliendo raised the firm’s terms people connected McKesson Corporation (NYSE:MCK) to $1,050 from $1,000 and maintained a Buy standing connected the shares. Caliendo said that contempt the “messy” Q4 print, the archetypal FY27 outlook looks “good enough.”

McKesson Corporation (NYSE:MCK) provides healthcare services successful the United States and internationally.

While we admit the imaginable of MCK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.